Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responsiveness after SARS-CoV-2 mRNA vaccination in immunocompromised adults
2021-000291-11Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Humoral immunogenicity one month after second vaccination. Started May 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000291-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000291-11.